Eylea (VEGF Trap-eye) has been approved by the FDA. The drug achieves the same results as Lucentis but after a monthly injection for three months it is then injected every two months. Pricewise it is similar to Lucentis. The potential of achieving the same efficacy with less frequent injections and monitoring offers a cost savings to consumers as well as a time saving benefit.
SEE FULL STORY [7]
|
|
Links:
[1] http://www.macula.org/category/disease/amd
[2] http://www.macula.org/category/categories/current-therapies
[3] http://www.macula.org/category/treatment/drug-therapy
[4] http://www.macula.org/category/disease/neovascularization
[5] http://www.macula.org/category/anatomy/macula
[6] http://www.macula.org/category/anatomy/retina
[7] http://investor.regeneron.com/releasedetail.cfm?releaseid=625771